EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Value of Tumor Regression Systems and Lymph Node Regression in Gastric Adenocarcinoma After Neoadjuvant Chemotherapy

Prognostischer Wert von Tumorregressionssystemen und Lymphknotenregression beim Magenadenokarzinom nach neoadjuvanter Chemotherapie

Özgecan Gündoğar, Sibel Bektaş, Hüseyin Karatay, Esra Paşaoğlu, Tevhide Bilgen Özcan, Nilsen Yıldırım Erdoğan, Pelin Akbaş, Emine Yıldırım, Sercan Yüksel, Özlem Özkul

Annali Italiani di Chirurgia · 10.01.2026 · 97 (1)

DOI: 10.62713/aic.4201 ↗

Auf einen Blick

Bei 134 Patient:innen mit lokal fortgeschrittenem Magenadenokarzinom waren JGCA2017-Subgruppen und eine positive Lymphknotenregression mit besserem Überleben assoziiert. Andere TRG-Systeme blieben in multivariablen Modellen nicht signifikant.

Fragestellung

Wie prognostisch relevant sind verschiedene histologische TRG-Systeme und die Lymphknotenregression nach NACT bei lokal fortgeschrittenem Magenadenokarzinom?

Methode

Retrospektive Kohortenstudie mit 134 Patient:innen von Januar 2020 bis März 2024; Auswertung von TRG-Systemen und Lymphknotenregression nach Gastrektomie; Kaplan–Meier, Log-Rank und Cox-Regression.

Ergebnisse

Medianes Follow-up 24 Monate; medianes OS 18,7 Monate (95 %-KI 16,2–21,3), medianes DFS 16,4 Monate (95 %-KI 14,1–18,7). JGCA2017 Score 0 und 1a sowie positive LN-Regeneration/Regression waren unabhängige Prädiktoren für OS und DFS.

Schlussfolgerung der Autor:innen

JGCA2017-Subgruppen sind laut Autor:innen die robustesten Prognoseindikatoren für OS und DFS nach NACT. Eine positive Lymphknotenregression ist ebenfalls ein unabhängiger protektiver Faktor.

Kernaussagen

  • JGCA2017 Score 0 und 1a sagten besseres OS und DFS voraus
  • Positive Lymphknotenregression war protektiv
  • Andere TRG-Systeme blieben in Multivarianz nicht signifikant

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Annali Italiani di Chirurgia, online erschienen am 10.01.2026. Verfasst von Özgecan Gündoğar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Gaziosmanpaşa Training and Research Hospital, University of Health Sciences, 34255 Istanbul, Turkey. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Neoadjuvant Therapy, Lymph Nodes. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: This study aimed to assess the prognostic significance of various histologic tumor regression grade (TRG) systems (Becker, American Joint Committee on Cancer (AJCC)/College of American Pathologists (CAP), Japanese Gastric Cancer Association (JGCA), JGCA2017, China, Mandard) and lymph node (LN) regression in patients with locally advanced gastric adenocarcinoma who underwent gastrectomy following neoadjuvant chemotherapy (NACT). METHODS: A retrospective cohort of 134 patients with locally advanced gastric adenocarcinoma from January 2020 to March 2024 who received NACT followed by gastrectomy was analyzed. Due to incomplete records, only the fact that patients received NACT was used, without specific regimen details. Surgical specimens were evaluated by two pathologists according to Becker, AJCC/CAP, JGCA, JGCA2017, China, and Mandard TRG systems. LN regression was categorized as positive/negative and coded as three categories (Code 1: metastasis without regression; Code 2: metastasis with regression; Code 3: regression without metastasis). Clinicopathologic variables, overall survival (OS) and disease-free survival (DFS) were analyzed by Kaplan–Meier curves and log-rank tests. Univariable and multivariable Cox regression models included each TRG subgroup as dummy variables and relevant covariates. Statistical significance was defined as p < 0.05. RESULTS: The median follow-up time was 24 months (range 6–60). The median OS was 18.7 months (95% CI 16.2–21.3), while the median DFS was 16.4 months (95% CI 14.1–18.7). In the univariable analysis, JGCA2017 Score 0 (hazard ratio [HR] 0.28; 95% CI 0.12–0.65; p = 0.003), Score 1a (HR 0.36; 95% CI 0.16–0.83; p = 0.017), and clinical N3 stage (HR 1.95; 95% CI 1.15–3.30; p = 0.013) were significantly associated with both OS and DFS. In multivariable Cox models, independent predictors of OS were JGCA2017 Score 0 (HR 0.25; 95% CI 0.11–0.59; p = 0.002), Score 1a (HR 0.33; 95% CI 0.15–0.76; p = 0.009), cN3 (vs cN1–2; HR 2.05; 95% CI 1.18–3.56; p = 0.010), and positive LN regression (HR 0.42; 95% CI 0.23–0.77; p = 0.005). Regarding DFS, JGCA2017 Score 0 (HR 0.30; 95% CI 0.12–0.75; p = 0.009), cN3 (vs cN1–2; HR 1.90; 95% CI 1.10–3.30; p = 0.020), and positive LN regression (HR 0.50; 95% CI 0.28–0.90; p = 0.018) were independent predictors. Other TRG systems' subgroups did not remain significant in multivariable models. Notably, the JGCA2017 Score 0/1a categories independently predicted better OS and DFS, whereas positive LN regression also emerged as a protective prognostic factor. CONCLUSIONS: JGCA2017 subgroups are the most robust prognostic indicators for OS and DFS in patients with gastric adenocarcinoma following NACT. Positive LN regression is also an independent protective factor. Prospective validation and international standardization of these grading systems are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAdenocarcinomaNeoadjuvant TherapyLymph NodesHumansRetrospective StudiesFemalePrognosisMaleMiddle AgedGastrectomyLymphatic MetastasisAgedChemotherapy, AdjuvantAdultDisease-Free SurvivalNeoplasm StagingNeoplasm GradingPathologic Complete Response

Stichwörter der Autor:innen

gastric adenocarcinomahistological tumor regressionlymph node regressionneoadjuvant chemotherapyprognostic factorssurvivaltumor regression grading systems

Autor:innen und Institutionen

  • Department of Pathology, Gaziosmanpaşa Training and Research Hospital, University of Health Sciences, 34255 Istanbul, Turkey.
  • Department of Pathology, Basakşehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey.
  • Department of Pathology, Bağcılar Training and Research Hospital, University of Health Sciences, 34200 Istanbul, Turkey.
  • Department of General Surgery, Istanbul Atlas University, 34203 Istanbul, Turkey.
  • Department of General Surgery, Basakşehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey.
  • Department of Medical Oncology, Bağcılar Training and Research Hospital, University of Health Science, 34200 Istanbul, Turkey.

Zitieren

APA

Gündoğar, Ö., Bektaş, S., Karatay, H., Paşaoğlu, E., Özcan, T. B., Yıldırım Erdoğan, N., Akbaş, P., Yıldırım, E., Yüksel, S., & Özkul, Ö. (2026). Prognostic Value of Tumor Regression Systems and Lymph Node Regression in Gastric Adenocarcinoma After Neoadjuvant Chemotherapy. Annali Italiani di Chirurgia, 97(1). https://doi.org/10.62713/aic.4201

Vancouver

Gündoğar Ö, Bektaş S, Karatay H, Paşaoğlu E, Özcan TB, Yıldırım Erdoğan N, et al. Prognostic Value of Tumor Regression Systems and Lymph Node Regression in Gastric Adenocarcinoma After Neoadjuvant Chemotherapy. Annali Italiani di Chirurgia. 2026;97(1). doi:10.62713/aic.4201

BibTeX
@article{Gndoar2026,
  author = {Gündoğar, Özgecan and Bektaş, Sibel and Karatay, Hüseyin and Paşaoğlu, Esra and Özcan, Tevhide Bilgen and Yıldırım Erdoğan, Nilsen and Akbaş, Pelin and Yıldırım, Emine and Yüksel, Sercan and Özkul, Özlem},
  title = {Prognostic Value of Tumor Regression Systems and Lymph Node Regression in Gastric Adenocarcinoma After Neoadjuvant Chemotherapy},
  journal = {Annali Italiani di Chirurgia},
  year = {2026},
  volume = {97},
  number = {1},
  doi = {10.62713/aic.4201}
}
Kostenlos starten →